(Q28076077)

main subject

venous thromboembolism

3 references

22 March 2019

17 June 2019

12 December 2020

1 reference

2 references

12 December 2020

Allison E. Burnett

1

1 reference

Charles E. Mahan

2

1 reference

Sara R. Vazquez

3

1 reference

Lynn B. Oertel

4

1 reference

David A. Garcia

5

1 reference

Jack Ansell

6

1 reference

language of work or name

1 reference

January 2016

1 reference

Journal of Thrombosis and Thrombolysis

1 January 2016

3 references

22 March 2019

17 June 2019

12 December 2020

4 references

22 March 2019

17 June 2019

12 December 2020

41

1 reference

issue

1

1 reference

page(s)

206-32

1 reference

Creative Commons Attribution 4.0 International

copyright license

3 references

Europe PubMed Central

22 March 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

on focus list of Wikimedia project

12 December 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Reversal of target-specific oral anticoagulants

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Idarucizumab for Dabigatran Reversal

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Dabigatran versus warfarin in patients with atrial fibrillation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Edoxaban versus warfarin in patients with atrial fibrillation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Apixaban versus warfarin in patients with atrial fibrillation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Oral rivaroxaban for symptomatic venous thromboembolism

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Features of electronic health records necessary for the delivery of optimized anticoagulant therapy: consensus of the EHR Task Force of the New York State Anticoagulation Coalition

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Direct oral anticoagulants: integration into clinical practice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Stroke prevention in patients with atrial fibrillation and renal dysfunction

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

New oral anticoagulants in patients with cancer: current state of evidence

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

The newer direct oral anticoagulants: a practical guide.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention o

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Pros and cons of new oral anticoagulants

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

A comparison of results of the US food and drug administration's mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Management and outcomes of major bleeding during treatment with dabigatran or warfarin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Transitions of care in anticoagulated patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Management of antithrombotic therapy in patients undergoing invasive procedures

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Reversal of target-specific oral anticoagulants

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

The impact of pharmacist-directed patient education and anticoagulant care coordination on patient satisfaction

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

The laboratory and the direct oral anticoagulants

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

The P-glycoprotein transport system and cardiovascular drugs.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Patients with lower activation associated with higher costs; delivery systems should know their patients' 'scores'.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

New oral anticoagulants: which one should my patient use?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Coagulation assays and anticoagulant monitoring

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

How I treat anticoagulated patients undergoing an elective procedure or surgery

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

FDA drug safety communications: a narrative review and clinical considerations for older adults

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Rivaroxaban in patients with a recent acute coronary syndrome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Apixaban with antiplatelet therapy after acute coronary syndrome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Dabigatran etexilate: a new oral thrombin inhibitor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

A case of rivaroxaban associated intracranial hemorrhage

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition).

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Oral apixaban for the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

How I treat target-specific oral anticoagulant-associated bleeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

New oral anticoagulant agents - general features and outcomes in subsets of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Treating Acute Venous Thromboembolism — Shift with Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1310-7

Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Pulmonary embolism due to interaction between rivaroxaban and carbamazepine

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Dabigatran overdose secondary to acute kidney injury and amiodarone use.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715848

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

27 November 2018

1 reference

12 December 2020

Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists

1 reference

12 December 2020

New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome

1 reference

12 December 2020

Bleeding Risk with Dabigatran in the Frail Elderly

1 reference

12 December 2020

Cerebral hemorrhage under rivaroxaban

1 reference

12 December 2020

Apixaban for extended treatment of venous thromboembolism

1 reference

12 December 2020

Oral anticoagulation with rivaroxaban during pregnancy: a case report

1 reference

12 December 2020

In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban

1 reference

12 December 2020

Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism

1 reference

12 December 2020

Use of PER977 to reverse the anticoagulant effect of edoxaban

1 reference

12 December 2020

Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model

1 reference

12 December 2020

Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism

1 reference

12 December 2020

Safety of recombinant activated factor VII in randomized clinical trials

1 reference

12 December 2020

Dabigatran etexilate linked to fatal gastrointestinal hemorrhage

1 reference

12 December 2020

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial

1 reference

12 December 2020

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers

1 reference

12 December 2020

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

12 December 2020

10.1007/S11239-015-1310-7

Identifiers

DOI

0 references

1 reference

PubMed publication ID

26780747

1 reference